NCT07619443PHASE1RecruitingAccepts Healthy Volunteers

A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

Merck Sharp & Dohme LLC

Start Date

7/1/2026

Completion Date

9/12/2026

Summary

The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.

Eligibility Criteria

Age Range: 19 years to 55 years

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health before randomization * Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history or presence of clinically significant medical or psychiatric condition or disease * Has a history of cancer

Interventions

DRUG

MK-7262

DRUG

Enlicitide

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Healthy

Locations

Celerion ( Site 0001)

Lincoln, Nebraska 68502

United States